Menu
Menu
MTAP deletion is rapidly emerging as a clinically actionable biomarker across multiple tumor types, frequently associated with a poor prognosis. While this is driving new therapeutic opportunities, it also exposes a major challenge for precision oncology trials: accurately testing for difficult and novel biomarkers. In Europe, especially, this gap continues to delay clinical trial enrolment and slow therapeutic progress.
In this webinar, we will explore how SOPHiA GENETICS, in partnership with ARC Regulatory, is addressing these challenges by implementing a comprehensive genomic profiling assay to enable biomarker identification and patient enrolment for clinical trials across Europe. By combining SOPHiA GENETICS’ AI-powered technology with ARC Regulatory’s expertise in assay implementation and workflow validation, we accelerate CTA development in instances such as MTAP deletion. Together, we aim to reduce regulatory risk in clinical research programs, shorten timelines for clinical trial recruitment, and broaden clinical trial recruitment in Europe.
Join us to gain insights into the nuances of European clinical trial testing and how robust genomic solutions can advance precision oncology research and ultimately improve patient outcomes.
Speakers:
San Sebastián, Donostia, Basque Country | Real Sociedad Arena
Join us in the vibrant coastal city of San Sebastián for the SOPHiA GENETICS Innovation Summit 2026.
From June 24-25, 2026, our global community of healthcare leaders, researchers, clinicians, and BioPharma innovators will come together for another year to explore the breakthroughs transforming oncology and rare disease care.
Join us at the spectacular Real Sociedad Arena for a memorable community experience! This iconic venue, home to one of Spain’s most celebrated football clubs, will provide a dynamic and inspiring setting for our community to connect, learn, and innovate.
Building on the success of our inaugural event in Rolle, Switzerland in 2025, this next chapter will spark thought-provoking discussions, unveil forward-thinking technologies, and offer unparalleled networking opportunities - in a city renowned for its innovation and culture!
Don’t miss this unique opportunity to engage with peers, deepen collaborations, and stay at the forefront of precision medicine, in one of Spain’s most iconic locations.
We are glad to return to Swiss Biotech Day 2026, where you will have the chance to meet our BioPharma and Medical teams for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine.
SOPHiA GENETICS is thrilled to be back at ASCO 2026! Meet our experts at booth #32131 to hear about our biopharma solutions. Learn how we are leveraging our unique AI expertise, to provide an unparalleled offering, unlocking insights from complex data types, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines
We are thrilled to be the inaugural World Companion Diagnostics & Liquid Biopsy Summit Japan. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
SOPHiA GENETICS is thrilled to be back at AACR 2026! Visit us at booth #4248 to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions. By harnessing the power of AI and multimodal data-driven analytics, we enable you to advance and streamline global access to precision therapies.
If you are around, don’t miss our Poster presentation on Wednesday, April 22nd, from 9.00 am to 12.00 pm.
Poster #7820: CHIP detection in solid tumors differs between liquid biopsy testing approaches.
Florian Klemm, Technical Product Management Expert, SOPHiA GENETICS
We are thrilled to be back at 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
The SOPHiA GENETICS team is looking forward to seeing you join our Pre-Conference Workshop Day and Plenary Talk.
Pre-Conference Workshop Day on Monday, March 30th, from 2.30 to 4.30 pm.
“Pioneering Precision Medicine: A Hybrid Future for CDx”
In this workshop, we will explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access in precision medicine.
This is an invitation-only workshop session. If you are interested in attending, please fill out our Engager Form
Plenary talk on Tuesday, March 31st, from 12.00 to 12.30 pm.
“Establishing a Scalable Liquid Biopsy Strategy: Foundations of a Global CDx Ecosystem”
Florian Klemm, Technical Product Management Expert, SOPHiA GENETICS
The future of translational research and the most exciting advances are happening at the intersection of AI, multi-omics, biomarker development, and biospecimen strategy, each essential for capturing the biological variability that shapes precision medicine. This panel brings together scientists, technologists, and strategists driving the next generation of biomarker & diagnostic discovery and validation. You’ll hear from leaders at Precision for Medicine, SOPHiA GENETICS, and Olink, part of Thermo Fisher; partners at the forefront of multi-omics integration, AI-powered analytics, genomics and high-plex proteomics as they discuss leading-edge practices and where the field is headed in 2026.
Key Discussion Topics:
Who Should Attend:
Built for biotech, pharma, and diagnostic researchers who are shaping the next generation of precision medicine:
Speakers:
Deb Phippard Chief Scientific Officer, Precision for Medicine
Philippe Menu EVP, Chief Medical Officer & Chief Product Officer, SOPHiA GENETICS
Heng (Tony) Qian Head of Data Science (North America), Olink, part of Thermo Fisher Scientific
Rob Fannon Head of Biospecimen Solutions, Precision for Medicine
SOPHiA GENETICS is excited to attend this year’s Association of Molecular Pathology (AMP) Annual Meeting!
Find us at booth #921 to learn about how we are enabling breakthrough innovations in cancer research.
Wednesday, November 12, 10:00 – 10:50 am | Corporate Workshops | 160C Level 1
Elevating CGP with Agile Solutions: The New MSK-IMPACT® Flex powered with SOPHiA DDM™
Speakers:
Wednesday, November 12, 11:00 – 11:50 am | Corporate Workshops | 160C Level 1
Redefining Precision Oncology with MSK-ACCESS® powered with SOPHiA DDM™
Speakers:
Friday, November 14, 9:15am – 10:15am | Poster number: ST044
Robust RNA profiling using the SOPHiA DDM™ RNAtarget Oncology Solution with FFPE tumor samples
Authored by: Izabela Matyszczak, Slawomir Kubik, Jonathan Bieler, Ewan Smith, Jonathan Lopez, Alexandre Harlé, Christian Pozzorini, Zhenyu Xu
Saturday, November 15, 9:15am – 10:15am | Poster number: ST041
MSK-IMPACT Flex powered with SOPHiA DDM™ enables sample-specific comprehensive genomic profiling through selective analysis of DNA and RNA biomarkers
Authored by: Izabela Matyszczak, Christian Pozzorini, Gregoire André, Tommaso Coletta, Amjad Alkodsi, Frederic Michaud, Yvan Wenger, Elia Magrinelli, Anjali Anjali, Zhenyu Xu
We are thrilled to be back at 15th World Clinical Biomarkers & Companion Diagnostics Summit. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
If you are attending, don’t miss:
Lunch & Learn hosted by SOPHiA GENETICS on Wednesday, September 24th, from 1.10 to 2.10 pm.
Join us for a special lunch session spotlighting the journey of MSK-ACCESS® powered with SOPHiA DDM™ from an in-house solution at Memorial Sloan Kettering Cancer Center (MSK) to a globally scalable, decentralized, best-in-class liquid biopsy platform, through a strategic collaboration with SOPHiA GENETICS.
Talk on Thursday, September 25th, from 11.00 to 11.30 am, in Track A.
“Bridging the Gap: A Hybrid Deployment Model for Scaling Innovation in Oncology”
Jess Lambe, Vice President and Managing Director of BioPharma Business Development, SOPHiA GENETICS
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.